Friday, April 12, 2013 5:13:56 PM
None of this R/S stuff even matters, other than the fact that its usually a BAD THING to r/s shares of stock.
Everyone knew the company had to reverse split it's shares by April 26th. The intelligent thing to do was to sell into the twitter poster/SA article pump run to .35/share and buy it back much lower, once that pump failed to deliver its promised result.
As far as the R/S ?
It was in the SEC filings.
Talk of extensions and such was just pure speculation.
April 19th it is.
Everyone knew the company had to reverse split it's shares by April 26th. The intelligent thing to do was to sell into the twitter poster/SA article pump run to .35/share and buy it back much lower, once that pump failed to deliver its promised result.
As far as the R/S ?
It was in the SEC filings.
Talk of extensions and such was just pure speculation.
April 19th it is.
Recent IGC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:14 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/03/2025 09:05:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/14/2025 10:27:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 03:03:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/21/2025 12:47:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/21/2025 12:44:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 08:40:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2025 08:02:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/18/2025 07:02:22 PM
